vs

Side-by-side financial comparison of ALLIANCE RESOURCE PARTNERS LP (ARLP) and BIO-RAD LABORATORIES, INC. (BIO). Click either name above to swap in a different company.

BIO-RAD LABORATORIES, INC. is the larger business by last-quarter revenue ($693.2M vs $516.0M, roughly 1.3× ALLIANCE RESOURCE PARTNERS LP). BIO-RAD LABORATORIES, INC. runs the higher net margin — 103.9% vs 2.1%, a 101.8% gap on every dollar of revenue. On growth, BIO-RAD LABORATORIES, INC. posted the faster year-over-year revenue change (3.9% vs -3.6%). BIO-RAD LABORATORIES, INC. produced more free cash flow last quarter ($119.1M vs $13.3M). Over the past eight quarters, BIO-RAD LABORATORIES, INC.'s revenue compounded faster (6.5% CAGR vs -6.7%).

Alliance Resource Partners LP is a leading North American natural resource enterprise primarily engaged in the production and marketing of coal for utility and industrial customers. It also operates complementary business segments including mineral royalty management, oil and gas extraction, and logistics support services.

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.

ARLP vs BIO — Head-to-Head

Bigger by revenue
BIO
BIO
1.3× larger
BIO
$693.2M
$516.0M
ARLP
Growing faster (revenue YoY)
BIO
BIO
+7.5% gap
BIO
3.9%
-3.6%
ARLP
Higher net margin
BIO
BIO
101.8% more per $
BIO
103.9%
2.1%
ARLP
More free cash flow
BIO
BIO
$105.8M more FCF
BIO
$119.1M
$13.3M
ARLP
Faster 2-yr revenue CAGR
BIO
BIO
Annualised
BIO
6.5%
-6.7%
ARLP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ARLP
ARLP
BIO
BIO
Revenue
$516.0M
$693.2M
Net Profit
$10.7M
$720.0M
Gross Margin
49.8%
Operating Margin
4.2%
-17.2%
Net Margin
2.1%
103.9%
Revenue YoY
-3.6%
3.9%
Net Profit YoY
200.6%
EPS (diluted)
$26.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARLP
ARLP
BIO
BIO
Q1 26
$516.0M
Q4 25
$535.5M
$693.2M
Q3 25
$571.4M
$653.0M
Q2 25
$547.5M
$651.6M
Q1 25
$540.5M
$585.4M
Q4 24
$590.1M
$667.5M
Q3 24
$613.6M
$649.7M
Q2 24
$593.4M
$638.5M
Net Profit
ARLP
ARLP
BIO
BIO
Q1 26
$10.7M
Q4 25
$82.7M
$720.0M
Q3 25
$95.1M
$-341.9M
Q2 25
$59.4M
$317.8M
Q1 25
$74.0M
$64.0M
Q4 24
$16.3M
$-715.8M
Q3 24
$86.3M
$653.2M
Q2 24
$100.2M
$-2.2B
Gross Margin
ARLP
ARLP
BIO
BIO
Q1 26
Q4 25
49.8%
Q3 25
52.6%
Q2 25
53.0%
Q1 25
52.3%
Q4 24
51.2%
Q3 24
54.8%
Q2 24
55.6%
Operating Margin
ARLP
ARLP
BIO
BIO
Q1 26
4.2%
Q4 25
18.2%
-17.2%
Q3 25
18.4%
10.0%
Q2 25
16.2%
11.8%
Q1 25
17.4%
4.0%
Q4 24
2.6%
8.7%
Q3 24
16.5%
9.9%
Q2 24
19.8%
15.9%
Net Margin
ARLP
ARLP
BIO
BIO
Q1 26
2.1%
Q4 25
15.4%
103.9%
Q3 25
16.6%
-52.4%
Q2 25
10.9%
48.8%
Q1 25
13.7%
10.9%
Q4 24
2.8%
-107.2%
Q3 24
14.1%
100.5%
Q2 24
16.9%
-339.2%
EPS (diluted)
ARLP
ARLP
BIO
BIO
Q1 26
Q4 25
$26.59
Q3 25
$-12.70
Q2 25
$11.67
Q1 25
$2.29
Q4 24
$-25.89
Q3 24
$23.34
Q2 24
$-76.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARLP
ARLP
BIO
BIO
Cash + ST InvestmentsLiquidity on hand
$28.9M
$1.5B
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$7.5B
Total Assets
$2.9B
$10.6B
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARLP
ARLP
BIO
BIO
Q1 26
$28.9M
Q4 25
$71.2M
$1.5B
Q3 25
$94.5M
$1.4B
Q2 25
$55.0M
$1.4B
Q1 25
$81.3M
$1.7B
Q4 24
$137.0M
$1.7B
Q3 24
$195.4M
$1.6B
Q2 24
$203.7M
$1.6B
Total Debt
ARLP
ARLP
BIO
BIO
Q1 26
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
Q1 25
Q4 24
$1.2B
Q3 24
Q2 24
Stockholders' Equity
ARLP
ARLP
BIO
BIO
Q1 26
Q4 25
$7.5B
Q3 25
$6.7B
Q2 25
$7.1B
Q1 25
$6.7B
Q4 24
$6.6B
Q3 24
$7.5B
Q2 24
$6.8B
Total Assets
ARLP
ARLP
BIO
BIO
Q1 26
$2.9B
Q4 25
$2.9B
$10.6B
Q3 25
$2.9B
$9.7B
Q2 25
$2.9B
$10.2B
Q1 25
$2.9B
$9.5B
Q4 24
$2.9B
$9.4B
Q3 24
$3.0B
$10.6B
Q2 24
$3.1B
$9.7B
Debt / Equity
ARLP
ARLP
BIO
BIO
Q1 26
Q4 25
0.16×
Q3 25
0.18×
Q2 25
Q1 25
Q4 24
0.18×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARLP
ARLP
BIO
BIO
Operating Cash FlowLast quarter
$164.9M
Free Cash FlowOCF − Capex
$13.3M
$119.1M
FCF MarginFCF / Revenue
2.6%
17.2%
Capex IntensityCapex / Revenue
18.5%
6.6%
Cash ConversionOCF / Net Profit
0.23×
TTM Free Cash FlowTrailing 4 quarters
$342.2M
$374.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARLP
ARLP
BIO
BIO
Q1 26
Q4 25
$143.9M
$164.9M
Q3 25
$209.9M
$120.9M
Q2 25
$151.7M
$116.5M
Q1 25
$145.7M
$129.9M
Q4 24
$168.4M
$124.2M
Q3 24
$209.3M
$163.6M
Q2 24
$215.8M
$97.6M
Free Cash Flow
ARLP
ARLP
BIO
BIO
Q1 26
$13.3M
Q4 25
$99.1M
$119.1M
Q3 25
$145.2M
$89.2M
Q2 25
$84.7M
$70.8M
Q1 25
$58.9M
$95.5M
Q4 24
$75.3M
$81.2M
Q3 24
$99.0M
$123.4M
Q2 24
$114.3M
$55.4M
FCF Margin
ARLP
ARLP
BIO
BIO
Q1 26
2.6%
Q4 25
18.5%
17.2%
Q3 25
25.4%
13.7%
Q2 25
15.5%
10.9%
Q1 25
10.9%
16.3%
Q4 24
12.8%
12.2%
Q3 24
16.1%
19.0%
Q2 24
19.3%
8.7%
Capex Intensity
ARLP
ARLP
BIO
BIO
Q1 26
18.5%
Q4 25
8.4%
6.6%
Q3 25
11.3%
4.9%
Q2 25
12.2%
7.0%
Q1 25
16.1%
5.9%
Q4 24
15.8%
6.4%
Q3 24
18.0%
6.2%
Q2 24
17.1%
6.6%
Cash Conversion
ARLP
ARLP
BIO
BIO
Q1 26
Q4 25
1.74×
0.23×
Q3 25
2.21×
Q2 25
2.55×
0.37×
Q1 25
1.97×
2.03×
Q4 24
10.31×
Q3 24
2.43×
0.25×
Q2 24
2.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARLP
ARLP

Coal sales$443.3M86%
Oil & gas royalties$41.3M8%
Other revenues$22.8M4%
Transportation revenues$8.6M2%
Tons Produced$8.0M2%
Mineral Interest Volumes (BOE)$1.0M0%

BIO
BIO

Clinical Diagnostics$425.3M61%
Life Science$267.9M39%

Related Comparisons